CTLA4 and cancer: Starting with the approval of anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death-1 (PD-1) gained by FDA, immune checkpoint inhibitors (ICIs) have made indelible achievements in cancer immunotherapy 4.